Drug Profile
Research programme: adenovector-based therapeutics and vaccines - GenVec/Washington University at St. Louis
Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator GenVec; Washington University
- Developer GenVec
- Class Antibodies; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilia
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for research development in Haemophilia in USA
- 16 Jun 2017 GenVec has been acquired by Intrexon Corporation
- 05 Jan 2017 GenVec enters into an option agreement with Washington University to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting